Our Lung, Head and Neck (LHN) Cancer Training Program (LHNTP), funded since 2013, is a multi-disciplinary translational program with a mission to train the next generation of researchers and physician scientists in LHN cancers. Although our T32 program is less than five years old and the majority of our trainees are still in training, the LHNTP value-added to our trainee's development has become obvious. This competitive renewal will continue our mission and further improve and strengthen our program based on the advances in research and clinical practice in the past few years. Our changes include training faculty, curriculum and activities that better incorporate expertise, innovative research and clinical advances. These changes will accelerate scientific discoveries, further enrich training environment and enhance career development. Based on the NCI's postdoctoral/predoctoral ratio requirement, we will continue to appoint 3 new postdoctoral fellows and 1 new predoctoral student per award year. Training faculty are selected from members of UCCC and graduate faculty based on their scientific/clinical expertise, track records of mentorship and active funding to achieve training of translational LHN cancer research. Our faculty members are from both basic science and clinical departments. In addition to laboratory training, we have designed mandatory didactic coursework for all trainees and clinical coursework for non-MD trainees to enhance the trainee's scientific background and the translational aspect of our program. Our specific goal is that program trainees will acquire the professional skills for productive academic careers in basic and translational LHN cancer research. We will vigorously select trainees from external and internal trainee pools based on their academic records and commitment to LHN cancer research.

Public Health Relevance

Training specifically devoted to lung, head and neck cancer research will expand the workforce and future scientific and clinical leaders to enhance progress toward establishing new therapies and better outcomes for patients with these cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Luo, Jingjing; Bian, Li; Blevins, Melanie A et al. (2018) Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res :
Mishall, Katie M; Beadnell, Thomas C; Kuenzi, Brent M et al. (2017) Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget 8:103014-103031
Dionne, Lai Kuan; Peterman, Eric; Schiel, John et al. (2017) FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation. J Cell Sci 130:4051-4062
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Oweida, Ayman; Bhatia, Shilpa; Hirsch, Kellen et al. (2017) Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol Carcinog 56:1189-1196
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Blevins, Melanie A; Huang, Mingxia; Zhao, Rui (2017) The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target. Mol Cancer Ther 16:981-990
Chen, Zhangguo; Gowan, Katherine; Leach, Sonia M et al. (2016) Unexpected effects of different genetic backgrounds on identification of genomic rearrangements via whole-genome next generation sequencing. BMC Genomics 17:823
Morton, J J; Bird, G; Keysar, S B et al. (2016) XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 35:290-300
Beadnell, Thomas C; Mishall, Katie M; Zhou, Qiong et al. (2016) The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther 15:1952-63

Showing the most recent 10 out of 27 publications